Health & Biotech
At Paradigm, we firmly believe that the key to addressing unmet medical needs lies in unlocking the potential of forgotten compounds. Our strategy is to take unconventional routes to develop safe and effective treatments for clinical conditions that lack viable options.
Our current primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA). An ability to provide a safe an effective treatment for OA is a blockbuster market opportunity as there are limited therapeutic solutions available. We’ve charged ahead into global phase 3 trials, addressing the core components of the disease: inflammation, pain, and regeneration. Zilosul® possesses the remarkable potential to provide long-term pain reduction and modify the underlying course of this debilitating disease.
With our headquarters in Melbourne, Australia, and strategic offices in the European Union and the United States, Paradigm is poised to make a global impact. Our international presence reflects our commitment to delivering ground breaking treatments to patients worldwide.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX stocks leading clinical trials in Australia
Stockhead TV
Break it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA support
News
Closing Bell: ASX choppy as traders sit it out; BPM soars on Mt Gibson gold find
Health & Biotech
Paradigm steps closer to Phase 3 trial for knee arthritis treatment after FDA feedback
Health & Biotech
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees
News
Market Highlights: Cryptos make their move ahead of Fed; and 5 ASX small caps to watch today
Health & Biotech
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech
ASX Quarterly Health Wrap – Who kicked off a pivotal trial last quarter?
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 2
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 1
Health & Biotech
ASX Quarterly Health Wrap: Which companies are making progress in clinical trials?
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Israel’s strikes grip markets; oil and gold spike while the ASX tumbles over 1pc
Health & Biotech
Paradigm makes key submission to US FDA to advance osteoarthritis Phase 3 trial
Health & Biotech